Xeris Biopharma Holdings, Inc. — Investor Relations & Filings

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company that develops and commercializes innovative, ready-to-use injectable and infusible therapies. The company utilizes its proprietary technology platforms to create liquid-stable drug formulations, which simplifies administration for patients and caregivers by eliminating the need for reconstitution. Its commercial portfolio features three FDA-approved products: Gvoke®, a ready-to-use glucagon for the treatment of severe hypoglycemia; Recorlev®, for endogenous Cushing's syndrome; and Keveyis®, for primary periodic paralysis. Xeris focuses on addressing unmet medical needs in various therapeutic areas, primarily in endocrinology and rare diseases.